Company news

CytomX Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer

July 5, 2022

CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference

May 31, 2022

CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors

May 25, 2022

CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

May 4, 2022

CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022

April 27, 2022

CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors

April 13, 2022

CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors

March 22, 2022

CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022

March 16, 2022

CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update

February 28, 2022

CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference

February 27, 2022

CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

February 21, 2022

CytomX Therapeutics Announces Promotion of Amy C. Peterson, M.D. to President and Chief Operating Officer

February 6, 2022

CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors

January 18, 2022

CytomX Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 4, 2022

CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate Targeting the Transferrin Receptor, CD71

December 19, 2021

CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

November 3, 2021

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Cytokine Platform at Society for Immunotherapy of Cancer Annual Meeting

October 31, 2021

CytomX Therapeutics to Announce Third Quarter 2021 Financial Results on November 4, 2021

October 27, 2021

CytomX Therapeutics Appoints Dr. Alan Ashworth to Board of Directors

October 3, 2021

CytomX Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

September 6, 2021

CytomX Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update

August 4, 2021

CytomX Therapeutics Announces Multiple Publications on Pacmilimab (CX-072), a Conditionally Activated Inhibitor of Programmed Death-Ligand 1 (PD-L1)

August 3, 2021

CytomX Therapeutics to Present at Upcoming August Investor Conferences

August 1, 2021

CytomX Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021

July 28, 2021

CytomX Therapeutics Announces Publication of First-in-Human Data for CX-2029 in Clinical Cancer Research

June 20, 2021

CytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference

May 26, 2021

CytomX Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update

May 5, 2021

CytomX Therapeutics to Announce First Quarter 2021 Financial Results on May 6, 2021

April 28, 2021

CytomX Therapeutics to Host Virtual Investor Event on April 7, 2021

March 23, 2021

CytomX Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

February 23, 2021

CytomX Therapeutics to Present at Upcoming March Virtual Investor Conferences

February 21, 2021

CytomX Therapeutics Announces New Employment Inducement Grant

February 18, 2021

CytomX Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021

February 16, 2021

CytomX Therapeutics to Present at Guggenheim Healthcare Talks 2021 Oncology Day

February 3, 2021

CytomX Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

February 2, 2021

CytomX Therapeutics Announces Closing of Public Offering of Common Stock

January 25, 2021

CytomX Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

January 19, 2021

CytomX Therapeutics Announces Proposed Public Offering of Common Stock

January 18, 2021

CytomX Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 6, 2021

CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors

December 21, 2020

CytomX Therapeutics to Present Updates on CX-2009 at 2020 San Antonio Breast Cancer Symposium

December 2, 2020

CytomX Therapeutics to Present at Upcoming Investor Conferences

November 10, 2020

CytomX Therapeutics Announces Treatment of First Patient in Phase 2 Expansion Study of CX-2029, an Anti-CD71 Probody Drug Conjugate

November 4, 2020

CytomX Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update

November 4, 2020

CytomX Therapeutics to Announce Third Quarter 2020 Financial Results

October 28, 2020

CytomX Therapeutics Announces the Planned Retirement of Chief Scientific Officer, W. Michael Kavanaugh, M.D.

October 5, 2020

CytomX Therapeutics to Participate in Upcoming Healthcare Conferences

September 1, 2020

CytomX Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update

August 5, 2020

CytomX Therapeutics to Participate in the 2020 Wedbush PacGrow Healthcare Conference

August 3, 2020

CytomX Therapeutics to Announce Second Quarter 2020 Financial Results

July 27, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 29 calls. Every call is listed under its year.

Decks

The 5 newest of 11 decks. Every deck is listed under its year.